Valuation: Seres Therapeutics, Inc.

Market Cap 33.3M 29.58M 27.66M 25.21M 47.46M 3.21B 48.11M 335M 130M 1.63B 125M 122M 5.25B P/E 2026 *
-0.95x
P/E 2027 * -0.68x
Enterprise Value 33.3M 29.58M 27.66M 25.21M 47.46M 3.21B 48.11M 335M 130M 1.63B 125M 122M 5.25B EV / Sales 2026 *
2.41x
EV / Sales 2027 * 122x
Free-Float
88.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day-12.54%
1 week-19.06%
Current month-12.54%
1 month-43.44%
3 months-63.10%
6 months-66.93%
Current year-80.31%
1 week 2.83
Extreme 2.83
3.7
1 month 2.83
Extreme 2.83
5.95
Current year 2.83
Extreme 2.83
16.42
1 year 2.83
Extreme 2.83
29.98
3 years 2.83
Extreme 2.83
47.6
5 years 2.83
Extreme 2.83
233.8
10 years 2.83
Extreme 2.83
770
Manager TitleAgeSince
Chief Executive Officer 70 02/03/2026
Chief Executive Officer 58 01/08/2025
President 51 02/03/2026
Director TitleAgeSince
Chairman 70 02/03/2026
Director/Board Member 50 15/01/2019
Director/Board Member 80 01/04/2015
Date Insider Type Main position Quantity % Market Cap. Importance
17/08/26 Sell

General Counsel

-82 0.0008%
17/08/26 Sell

Director

-263 0.0027%
17/08/26 Sell

Chief Operating Officer

-64 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
-12.54%-19.06%-85.71%-93.19% 33.3M
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.69%+36.36%+82.72% 60.14B
-2.54%-0.21%+6.34%+31.72% 48.15B
-3.02%-5.20%+27.94%+34.47% 44.25B
+0.31%+3.02%+348.95%+686.74% 43.99B
-1.96%-0.33%+7.04%+100.99% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-4.86%-10.66%-26.27%+328.03% 24.93B
Average -1.29%+0.61%+41.20%+133.97% 39.68B
Weighted average by Cap. +0.18%+1.83%+59.98%+150.77%

Financials

2026 *2027 *
Net sales 13.8M 12.25M 11.46M 10.44M 19.66M 1.33B 19.93M 139M 53.67M 677M 51.8M 50.68M 2.17B 274K 243K 227K 207K 390K 26.33M 395K 2.75M 1.06M 13.41M 1.03M 1M 43.07M
Net income -37.49M -33.3M -31.14M -28.38M -53.42M -3.61B -54.16M -377M -146M -1.84B -141M -138M -5.9B -78.95M -70.13M -65.58M -59.76M -113M -7.6B -114M -793M -307M -3.87B -296M -290M -12.43B
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
02/10/26 $2.930 -12.54% 247,315
30/09/26 $3.350 -3.74% 54,614
29/09/26 $3.480 -1.14% 71,289
28/09/26 $3.520 0.00% 55,485
25/09/26 $3.520 -2.76% 55,674
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.350USD
Average target price
17.00USD
Spread / Average Target
+407.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock